afatinib
afatinib is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Gilotrif. Available dosage form: tablet, film coated.
Drug details
- Generic Name
- afatinib
- Brand Names
- Gilotrif
- Application Number
- NDA201292
- Sponsor
- Boehringer Ingelheim Pharmaceuticals, Inc.
- NDC Codes
- 3
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- AFATINIB
Indications and Usage
1 INDICATIONS AND USAGE Afatinib tablets are a kinase inhibitor indicated for: • First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test ( 1.1 ) Limitations of Use : Safety and efficacy of afatinib tablets were not established in patients whose tumors have resistant EGFR mutations ( 1.1 ) • Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy ( 1.2 ) 1.1 EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer Afatinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1), Clinical Pharmacology (12.1), Clinical Studies (14.1)]. Limitations of Use : The safety and efficacy of afatinib tablets have not been established in patients whose tumors have resistant EGFR mutations [ see Clinical Studies (14.1)] . 1.2 Previously Treated, Metastatic Squamous NSCLC Afatinib tablets are indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.